Fotivda 1.34 MG capsule 21S
Ended Awarded Last action
- Contract number
- SPE2DR26F6X8L
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,188
Award facts
- Contract value 100% obligated
- $20,188.27 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $20,188.27 delivery order to AmerisourceBergen Drug Corp on January 23, 2026, for the supply of Fotivda (tivozanib) 1.34 mg capsules in quantities of 21 units. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of February 13, 2026. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026, which serves as the primary vehicle for supplying pharmaceutical products and medical commodities to military healthcare systems globally.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (doing business as AmerisourceBergen), is a major pharmaceutical distributor that serves as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The parent organization, Cencora, holds the underlying IDC agreement with DLA and has demonstrated extensive capability in fulfilling government contracts for specialized medications across multiple therapeutic domains, including oncology treatments such as Fotivda used in renal cell carcinoma management. The company's federal contract portfolio reflects its established position as a reliable supplier of essential pharmaceutical commodities to the Defense Health Agency and other federal medical institutions.
Quick answers
Who was awarded contract SPE2DR26F6X8L?
SPE2DR26F6X8L was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26F6X8L worth?
The government has obligated $20,188 on SPE2DR26F6X8L.
Is contract SPE2DR26F6X8L an order under another contract?
Yes. SPE2DR26F6X8L is a delivery order under SPE2DR25D3013, an indefinite delivery contract.
Was contract SPE2DR26F6X8L competed?
The extent of competition for SPE2DR26F6X8L was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award